MWNA
RXST icon

Marshall Wace North America’s RxSight RXST Stock Holding History

Marshall Wace North America’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$925K Buy
+73,070
New +$1.01M ﹤0.01% 951

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Marshall Wace North America's RXST Position: Q3 2021 in Review

Marshall Wace North America opened a new position in RxSight (RXST) in Q3 2021: 73,070 shares worth $925K. The stake represents ﹤0.01% of the portfolio and ranks #951 among its holdings.

39 funds tracked by Wall St. Rank hold RXST as of Q3 2021.

  • Marshall Wace North America held 73,070 shares of RxSight worth $925K as of Q3 2021.
  • RxSight was a new Marshall Wace North America position in Q3 2021.
  • RxSight made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #951 holding.
  • 39 funds tracked by Wall St. Rank held RxSight as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.